



Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

View Detailed Chart

244.900USD

-11.260-4.40%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

23.97BMarket Cap

LossP/E TTM



Beigene Ltd

244.900

-11.260-4.40%

Company

Intraday

30m

Today

-4.40%

5 Days

+6.03%

1 Month

+0.29%

6 Months

+15.08%

Year to Date

+32.59%

1 Year

+59.46%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 22 analysts

BUY

Current Rating

314.767

Target Price

28.53%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

556

Total

Median

Average

Company name

Ratings

Analysts

Beigene Ltd

ONC

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Moderna Inc

MRNA

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(1)

Buy(8)

Indicators

Sell(1)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

3.100

Buy

RSI(14)

60.660

Neutral

STOCH(KDJ)(9,3,3)

85.713

Overbought

ATR(14)

15.904

Low Volatility

CCI(14)

125.469

Buy

Williams %R

6.013

Overbought

TRIX(12,20)

0.191

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

243.652

Buy

MA10

236.666

Buy

MA20

238.529

Buy

MA50

222.222

Buy

MA100

209.456

Buy

MA200

195.565

Buy

News

More news coming soon, stay tuned...

Company

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Company codeONC

CompanyBeigene Ltd

CEOMr. John Victor Oyler

Websitehttps://www.beigene.com/